Dogwood Therapeutics (DWTX) Projected to Post Quarterly Earnings on Thursday

Dogwood Therapeutics (NASDAQ:DWTX) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 12:30 PM ET.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). On average, analysts expect Dogwood Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.66) EPS for the next fiscal year.

Dogwood Therapeutics Price Performance

Shares of Dogwood Therapeutics stock opened at $1.04 on Wednesday. Dogwood Therapeutics has a 12 month low of $0.90 and a 12 month high of $7.04. The business has a fifty day simple moving average of $1.62 and a two-hundred day simple moving average of $1.97.

Analyst Ratings Changes

A number of research firms have recently weighed in on DWTX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Thursday, October 22nd. HC Wainwright reissued a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dogwood Therapeutics presently has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.